Are genomic tests for prognostic risk at diagnosis really helpful (yet)?

One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …

Medicare to cover genetic/genomic testing in advanced cancers

In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing for Medicare patients with many advanced forms of cancer. … READ MORE …

Genomic testing and management of low-/intermediate-risk prostate cancer

A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer. … READ MORE …

New test now available for identification of AR-V7 mutations in mCRPC

According to a media release issued yesterday, Genomic Health has now made available a commercial test for risk of the AR-V7 mutation in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

The Metastatic Prostate Cancer Project: listen to the program

Yesterday evening we were pleased to be able to collaborate with CureTalks to host a conversation with Dr. Eli Van Allen — the principal investigator for the Metastatic Prostate Cancer Project — to “spread the word” about this initiative. … READ MORE …

CureTalk with Dr. Eli Van Allen on the “Metastatic Prostate Cancer Project”

On Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), we will be collaborating with CureTalks to present the next CureTalk on prostate cancer. It will address the recently launched “Metastatic Prostate Cancer Project”. … READ MORE …

Your genetics can accurately predict your age-related prostate cancer risk

Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …